trending Market Intelligence /marketintelligence/en/news-insights/trending/gcbz60PeLZJ6bDuklKQgWw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In this list

Dermira plans $110M common stock offering

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Dermira plans $110M common stock offering

Dermira Inc. plans to sell $110 million of its common shares in an underwritten public offering.

The biopharmaceutical company plans to grant the underwriters an option to buy up to an additional $16.5 million of its common stock in the offering.

Citigroup, Cowen, Cantor Fitzgerald & Co. and Guggenheim Securities are acting as book-runners, with Needham & Co. and H.C. Wainwright & Co. as co-managers.

Menlo Park, Calif.-based Dermira develops and commercializes therapies for patients with skin conditions. The company offers Qbrexza for the treatment of primary axillary hyperhidrosis — a certain condition in which excessive sweating occurs — in adults and pediatric patients nine years and older.